The Similasan Corporation, a renowned manufacturer of homeopathic remedies, has agreed to settle a class action lawsuit to the tune of $3.5 million over allegations of deceptive labeling and advertising practices. The lawsuit, which has broad implications for industries governed by the United States Food and Drug Administration (FDA), suggests that Similasan unlawfully marketed its eye drops as "homeopathic" drugs without appropriate FDA approvals. The violations allegedly occurred within the period of September 11, 2017, to February 20, 2025, and involved products sold under the Similasan, CVS, and Walgreens brands. The lawsuit, which has garnered significant attention, was predicated on the Florida Deceptive and Unfair Trade Practices Act. It asserted that Similasan had misled consumers about the nature and benefits of its products, violating industry regulations and fair trade practices. The settlement allows eligible consumers who have purchased Similasan's implicated products during the above-mentioned period to receive a payment of $2.50 per product.